PARP1 and cancer: Similarly to the case of Akt activation, JNK and p38 MAPK inhibition by the PARP inhibitor, and the resulting mitochondria- and cytoprotection are beneficial in the therapy of non-malignant diseases, yet impairs the PARP inhibitors’ therapeutic efficacy in cancer [112].